Fly News Breaks for October 7, 2019
Oct 7, 2019 | 08:36 EDT
JMP Securities analyst Donald Ellis initiated Sorrento Therapeutics with an Outperform rating and a price target of $21. The analyst cites the company's "attractive asset" Resiniferatoxin being ready for Phase 2/3 trials, which is targeting a multi-million patient markets in non-opioid pain therapy. Ellis also points to Sorrento seeking an FDA "breakthrough designation" for total knee arthroplasty deferment which, if granted, will initiate registration trials in Q1 of next year.
News For SRNE From the Last 2 Days
Nov 23, 2020 | 09:40 EST
Unusual total active option classes on open include: Ideanomics (IDEX), Gogo (GOGO), AstraZeneca (AZN), Harley Davidson (HOG), Marathon Patent Group (MARA), US Global Jets ETF (JETS), Lordstown Motors (RIDE), Western Digital (WDC), Workhorse Group (WKHS), and Sorrento Therapeutics (SRNE).